Literature DB >> 24982004

Cholinesterase inhibitors and add-on nutritional supplements in Alzheimer's disease: a systematic review of randomized controlled trials.

A Rijpma1, O Meulenbroek2, M G M Olde Rikkert3.   

Abstract

To date, single drug and nutrient-based interventions have failed to show a clinically relevant effect on Alzheimer's disease (AD). Multidomain interventions may alleviate symptoms and alter the disease course in a synergistic manner. This systematic review examines the effect of adding nutritional supplementation to cholinesterase inhibitors. A systematic PubMed and Cochrane search resulted in nine high quality studies. The studies had low to moderate risk of bias and focused on oxidative stress, homocysteine levels, membrane fluidity, inflammation and acetylcholine levels. Only the use of vitamin E supplements could reduce the rate of functional decline when combined with cholinesterase inhibitors in one study, whereas cognition was not affected in both this and other studies. None of the other nutritional supplements showed convincing evidence of a beneficial effect when combined with cholinesterase inhibitors. This shows that cognitive and functional improvement is difficult to achieve in patients with AD, despite epidemiological data and evidence of biological effects of nutritional supplements. Addressing one disease pathway in addition to cholinesterase inhibitor therapy is probably insufficient to alter the course of the disease. Personalized, multifactorial interventions may be more successful in improving cognition and daily functioning.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Cognition; Complex interventions; Dementia; Multidomain; Nutrition

Mesh:

Substances:

Year:  2014        PMID: 24982004     DOI: 10.1016/j.arr.2014.06.002

Source DB:  PubMed          Journal:  Ageing Res Rev        ISSN: 1568-1637            Impact factor:   10.895


  8 in total

1.  Treatment and Management of Dementia Due to Alzheimer's Disease.

Authors:  Jennifer Rose V Molano; Robin Bratt; Rhonna Shatz
Journal:  Curr Treat Options Neurol       Date:  2015-08       Impact factor: 3.598

Review 2.  Vitamin E for Alzheimer's dementia and mild cognitive impairment.

Authors:  Nicolas Farina; David Llewellyn; Mokhtar Gad El Kareem Nasr Isaac; Naji Tabet
Journal:  Cochrane Database Syst Rev       Date:  2017-01-27

Review 3.  Vitamin E for Alzheimer's dementia and mild cognitive impairment.

Authors:  Nicolas Farina; David Llewellyn; Mokhtar Gad El Kareem Nasr Isaac; Naji Tabet
Journal:  Cochrane Database Syst Rev       Date:  2017-04-18

4.  Timosaponin B-II ameliorates scopolamine-induced cognition deficits by attenuating acetylcholinesterase activity and brain oxidative damage in mice.

Authors:  Xu Zhao; Chunmei Liu; Yu Qi; Lina Fang; Jie Luo; Kaishun Bi; Ying Jia
Journal:  Metab Brain Dis       Date:  2016-07-22       Impact factor: 3.584

Review 5.  Dietary interventions in mild cognitive impairment and dementia.

Authors:  George S Vlachos; Nikolaos Scarmeas
Journal:  Dialogues Clin Neurosci       Date:  2019-03       Impact factor: 5.986

Review 6.  Alzheimer's Disease Risk and Progression: The Role of Nutritional Supplements and their Effect on Drug Therapy Outcome.

Authors:  A Giulietti; A Vignini; L Nanetti; L Mazzanti; R Di Primio; E Salvolini
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

7.  Involvement of Cholinergic Dysfunction and Oxidative Damage in the Effects of Simulated Weightlessness on Learning and Memory in Rats.

Authors:  Yongliang Zhang; Qiong Wang; Hailong Chen; Xinmin Liu; Ke Lv; Tingmei Wang; Yanli Wang; Guohua Ji; Hongqing Cao; Guanghan Kan; Yinghui Li; Lina Qu
Journal:  Biomed Res Int       Date:  2018-02-08       Impact factor: 3.411

8.  Analogous β-Carboline Alkaloids Harmaline and Harmine Ameliorate Scopolamine-Induced Cognition Dysfunction by Attenuating Acetylcholinesterase Activity, Oxidative Stress, and Inflammation in Mice.

Authors:  Shu-Ping Li; Yu-Wen Wang; Sheng-Lan Qi; Yun-Peng Zhang; Gang Deng; Wen-Zheng Ding; Chao Ma; Qi-Yan Lin; Hui-Da Guan; Wei Liu; Xue-Mei Cheng; Chang-Hong Wang
Journal:  Front Pharmacol       Date:  2018-04-10       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.